Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity

Trial Profile

A Phase 3 Trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jan 2019

At a glance

  • Drugs Setmelanotide (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Sponsors Rhythm
  • Most Recent Events

    • 04 Jan 2019 According to a Rhythm Pharmaceuticals media release, the company expects to complete pivotal enrollment of at least 20 patients with BBS and at least six patients with Alstrom Syndrome in the second half of 2019.
    • 13 Dec 2018 According to a Rhythm Pharmaceuticals media release, the company plans to continue enrolling supplemental patients following enrollment of the last pivotal patient in order to generate additional data regarding the safety and efficacy in people living with BBS and Alstrom Syndrome.
    • 13 Dec 2018 According to a Rhythm Pharmaceuticals media release, the first patient has been enrolled in this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top